Compare WKHS & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WKHS | LPCN |
|---|---|---|
| Founded | 2007 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.4M | 19.1M |
| IPO Year | 2008 | 2011 |
| Metric | WKHS | LPCN |
|---|---|---|
| Price | $3.79 | $2.36 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $21.00 | N/A |
| AVG Volume (30 Days) | ★ 266.5K | 187.9K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 86.92 | 46.18 |
| EPS | N/A | ★ N/A |
| Revenue | $763,173.00 | ★ $1,976,677.00 |
| Revenue This Year | $89.23 | N/A |
| Revenue Next Year | $28.84 | $92.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.53 | $1.81 |
| 52 Week High | $11.80 | $12.37 |
| Indicator | WKHS | LPCN |
|---|---|---|
| Relative Strength Index (RSI) | 61.71 | 34.20 |
| Support Level | $3.22 | $2.20 |
| Resistance Level | $4.26 | $2.50 |
| Average True Range (ATR) | 0.44 | 0.11 |
| MACD | 0.08 | 0.18 |
| Stochastic Oscillator | 74.32 | 49.98 |
Workhorse Group Inc is a technology company with a vision to pioneer the transition to zero-emission commercial vehicles. Its focus is to provide sustainable and cost-effective solutions to the commercial transportation sector. It designs and manufactures all-electric delivery trucks and drone systems, including the technology that optimizes the way these vehicles operate. It's focused on a core competency of bringing electric delivery vehicle platforms to serve the last-mile delivery market. Its products are marketed under the Workhorse brand.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.